News
In the MIDAS trial, ASCT showed no added MRD benefit over Isa-KRd in newly diagnosed myeloma, raising questions about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback